Better Artificial Intelligence Stock: Aehr Test Systems vs. Super Micro Computer

Super Micro Computer generated FY2026 revenue of $39.1 billion, up 77.8% year over year, and net income of $2.2 billion, versus Aehr Test Systems' $50.0 million revenue, down 15.2%, and $7.1 million net loss. Super Micro trades at 9.9x forward P/E and 0.6x sales, materially below Aehr's 117.7x and 55.5x, supporting the article's preference for SMCI despite its negative $7.0 billion free cash flow. Key risks for Super Micro include class-action and export-control-related issues, following prior delayed financial filings and indictments of former employees related to alleged AI-technology smuggling to China.

Analysis

SMCI’s apparent valuation discount should not be read as a clean AI-infrastructure bargain: the market is underwriting a lower-quality earnings stream because rapid rack integration is working-capital intensive, component allocation-dependent, and exposed to abrupt gross-margin resets. The key near-term variable is cash conversion rather than revenue growth; if inventory and receivables normalize while shipment growth remains elevated, the equity can rerate materially over the next 1-3 quarters. Conversely, another delayed filing, adverse export-control development, or margin deterioration would validate the discount and likely overwhelm earnings momentum.

AEHR is a far higher-beta, less diversified way to express a recovery in SiC and advanced semiconductor qualification spending, but it presently needs order evidence before its AI narrative is investable. Its balance sheet creates runway, not proof of demand recovery: with a small revenue base, a single program win or loss can dominate estimates and valuation. The more non-obvious read-through is that AI-related test demand may favor larger automated-test ecosystems such as Teradyne (TER) and Advantest (6857 JP) before it accrues to AEHR’s specialized platform, particularly if customers prioritize proven throughput and global service capacity.

Consensus may be too focused on SMCI’s headline growth versus AEHR’s weak operating leverage. SMCI’s upside requires a demonstrable improvement in free-cash-flow conversion, while AEHR’s upside requires bookings, backlog quality, and customer diversification—not merely broader AI capex. For the next 6-18 months, NVDA supply availability and hyperscaler capex discipline remain the shared gating variables, but AEHR has substantially greater idiosyncratic execution risk.

Key Decisions for Investors

• Maintain a tactical long SMCI only after the next filing confirms timely reporting and stable/improving gross margin; target a 3-6 month rerating on improved working-capital conversion. Exit on a renewed filing delay, material export-control action, or two consecutive quarters of gross-margin compression.
• Use a pair trade: long SMCI / short AEHR over 3-6 months, sized conservatively given AEHR’s high short-interest and single-contract upside. The thesis is relative earnings durability and valuation support; stop out if AEHR reports a material multi-customer bookings acceleration or SMCI guides to weaker revenue growth and margin simultaneously.
• Do not initiate a directional AEHR long absent independently verifiable backlog, customer-concentration, and order-timing disclosure. Set an alert for a quarterly bookings inflection plus positive operating cash flow; that combination would indicate demand recovery is becoming earnings-relevant rather than promotional.
• For broader AI hardware exposure, prefer NVDA or a diversified semiconductor-equipment basket over AEHR as the lower-idiosyncratic expression. Reassess if hyperscaler capex guidance weakens, since rack integrators such as SMCI should feel demand revisions faster than upstream chip suppliers.